In your interest.
Online Personal Finance Magazine
No beating about the bush.
Two years ago, Amgen’s David Beier estimated that the biotechnology industry had lost $100 billion in its three decades, but still enjoyed a stock market valuation of $500 billion. By the end of 2006, experience seemed to elbow aside hope. That year, investors yanked $6.4 billion from funds focused on biotechnology and healthcare in the US, the industry’s capital. They withdrew another $5.4...